AbbVie Sets Out To Win Over Investors In Its First Financial Call
This article was originally published in The Pink Sheet Daily
Executive Summary
Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.
You may also be interested in...
Abbvie’s Elagolix Looks Set To Stake Claim In Endometriosis
Abbvie plans 2017 filing for elagolix, licensed from Neurocrine, after second Phase III trial leaves the oral drug with a competitive profile.
Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 2 of 2)
Gilles Picard discusses how to reach patients across a mix of developed and frontier markets in his role as VP of Asia, Australia, Africa and the Middle East for AbbVie, the innovative biopharma company split from parent Abbott Laboratories at the start of the year.
Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 1 of 2)
Gilles Picard discusses how to reach patients across a mix of developed and frontier markets in his role as VP of Asia, Australia, Africa and the Middle East for AbbVie, the innovative biopharma company split from parent Abbott Laboratories at the start of the year.